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Abstract. Purpose: to study the feasibility of using the new radiopharmaceutical based on the 
technetium-99m-labeled gamma-alumina for identification of sentinel lymph nodes (SLNs) in 
breast cancer patients. Materials and methods. The study included two groups of breast cancer 
patients who underwent single photon emission computed tomography (SPECT) and 
intraoperaive gamma probe identification of sentinel lymph nodes (SLNs). To identify SLNs, 
the day before surgery Group I patients (n=34) were injected with radioactive 99mTc-Al203, 
and Group II patients (n=30) received 99mTc-labeled phytate colloid. Results. A total of 37 
SLNs were detected in Group I patients. The number of identified SLNs per patient ranged 
from 1 to 2 (the average number of identified SLNs was 1.08).  Axillary lymph nodes were the 
most common site of SLN localization. At 18 hours after 99mTc-Al203 injection, the 
percentage of its accumulation in the SLN was 7-11% (of the counts in the injection site) by 
SPECT and 17-31% by gamma probe detection. In Group II patients, SLNs were detected in 27 
patients. At 18 hours after injection of the phytate colloid, the percentage of its accumulation in 
the SLN was 1.5-2% out of the counts in the injection site by SPECT and 4-7% by gamma 
probe. Conclusion. The new radiopharmaceutical based on the 99mTc – Al203 demonstrates 
high accumulation in SLNs without redistribution through the entire lymphatic basin. 
Sensitivity and specificity of 99mTc – Al203 were 100% for both SPECT and intraoperative 
gamma probe identification.  
 
1. Introduction 
Development of the sentinel node concept started at the beginning of the 1990s with evaluation and 
comparison of the procedures that could be used to detect the sentinel node(s). 
If the SLN is free of metastatic disease, all other lymph nodes will also be free of disease [[1],[2]]. 
The use of colloid radiopharmaceuticals labeled with technetium-99m has appeared to be effective and 
safe for scintigraphic and/or intraoperative gamma probe identification of SLN [[2]]. Sentinel node 
biopsy may be a reasonable alternative to avoid extensive axillar lymph node dissection in breast 
cancer patients with negative SLNs, thereby improving the quality of life of approximately 100,000 
patients undergoing lymphodissection for treating breast cancer [[1],[3],[4],[5]]. The two most widely 
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accepted clinical scenarios for SLN biopsy are melanoma and breast cancer. Most modern medical 
centers worldwide now offer SLN biopsy for these malignancies, yet debate continues regarding 
whether SLN biopsy should be routinely used in clinical practice [[1],[2],[4],[6],[9]]. 
The size of radioactive particles is the most important factor in determining the choice of 
radiopharmaceuticals. Schauer AJ et al. [[5]] reported that a colloid with the particle size of less than 
50 nm can be accumulated not only in the SLN but also in the non-SLNs. Particles of greater than 100 
nm slowly migrate from the injection site. A colloid with the particle size of the order of 50-80 nm 
may be preferable for the SLN detection.  Nanocolloids made to date are based on the compounds that 
form stable hydrosols, and organic substances of different structures are often chosen as starting 
materials for their production. Another part of such pharmaceuticals represents inorganic complexes 
with 99mTc-rhenium sulfide and antimony, the application of which are limited by their complex 
manufacturing process and high cost. Our studies have shown that stable colloidal compounds can be 
obtained in a simpler way - by means of adsorption on the reduced 99mTc alumina gamma [[7],[8]]. 
The original premise for the use of alumina as a "carrier" of 99mTc- label is its relatively low toxicity, 
combined with good adsorption properties, availability and low cost.  
A specific feature of this compound is an organic coating of nanoparticles. During passage through 
the lymphatic system, nanoparticles lose their organic coating and accumulate in SLN without 
redistribution in the body.  
Breast cancer is the most common cancer in women worldwide. Approximately 30,000 new early 
stages breast cancer cases are diagnosed each year in Russia [[10]].  However, in patients with early 
stages of breast cancer, regional lymph node metastases are found in only 10-30% of cases. Extended 
lymph node dissection may increase the risk of postoperative complications [[10]]. 
The purpose of our study was to evaluate the feasibility of using the new radiopharmaceutical, 
based on technetium-99m-labeled gamma-alumina for the detection of sentinel lymph nodes in breast 
cancer patients.  
 
2. Materials and methods 
The study included 64 patients with histologically verified breast cancer (T1-2N0-1M0). For SLN 
visualization, all patients were divided into two groups. Group I consisted of 34 women, who received 
4 peritumoral injections of radioactive 99mTc-Al203 at a total dose of 80 MBq (20 MBq per 
quadrant), the day before surgery. Group II comprised 30 women, who were injected with phytate 
colloid at a total dose of 80 MBq (4 peritumoral injections, 20 MBq per injection), the day before 
surgery. 
All patients underwent single photon emission computed tomography (SPECT) using the dual-head 
gamma camera (E.CAM 180, Siemens, energy 140 keV, window 15%) in 18 hours after the 
radiotracer injection. A total of 16 projections were acquired (30 seconds per projection, matrix size 
64х64). The scan images were analyzed using the ESoft software (Siemens, Germany).  Three-
dimensional images of the sagittal, transverse and coronal sections were obtained.  To obtain 
quantitative values, the axial sections were used. The radiotracer accumulation in the SLN with respect 
to the injection site was evaluated using a quantitative criterion.  
For intraoperative detection of sentinel lymph nodes, the hand-held collimated Gamma Finder II® 
probe was used, which allowed the surgeon to precisely locate gamma radiation source and obtain 
accurate information about the distribution of the radionuclide in tissues and organs of the patient. The 
registered gamma radiation level was displayed in numerical values. The lymph node with 
radioactivity of at least three times more than the background counts was defined as a sentinel lymph 
node. 
The sentinel lymph node was marked and separately sent for express cytological examination. The 
lymph node was sectioned transversely into 2 mm slices. Depending on the size of the node, 6–10 
imprints were made from each slice by gently touching the cut surface of the node to a glass slide. 
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Cytological specimens were stained for 15 seconds using the kit for rapid staining of blood smears 
(Leucodiff 200) and examined with a Zeiss Axio Scope (Germany). 
Each group of the patients was subdivided into the groups with 12 patients who underwent 
extended lymphodissection despite the results of histological examination. After lymphodissection, the 
removed lymph nodes were re-examined with gamma probe to detect SLNs missed during 
intraoperative examination.  
 
3. Results and discussion 
A total of 37 SLNs were identified in Group I patients. The number of identified SLNs per patient 
ranged from 1 to 2 (the mean number of identified SLNs was 1.08). The most frequent SLN location 
was the axillary region (97.2%) (Figure 1). Metastases in the excised SLNs were detected in 9 patients 
(26.6%), who subsequently underwent the conventional axillary lymph node dissection. Four patients 
(11.4%) had metastases not only in the SLN but also in lymph nodes of the level II. The presence of 
SLN metastasis indicates lymphatic dissemination of tumor cells and the formation of clinically 
undetectable regional lymph node metastases. Sentinel lymph node was free from metastasis in 25 
patients (73.5%). We did not observe the phenomenon of so called “jumping” metastases in these 
patients. 
 
 
Figure 1. SPECT SLN detection in breast cancer patients. 
 
The 99mTc-Al203 uptake in the SLN in 18 hours after injection was 7-11% (of the radioactivity in 
the injection site) by SPECT and 17-31% by intraoperative gamma probe detection.  
Thus, the sensitivity and specificity of 99mTc-Al203 for detecting SLNs in breast cancer patients 
were 100%.  
The intraoperative SLN detection was performed through a small skin incision. Sparing surgical 
procedures can significantly reduce overall surgery trauma and recovery time (Figure 2). 
 
SLN 
Injection site 
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Figure 2. Intraoperative radio guided SLN detection with the use of the hand-held collimated gamma Finder II® 
in breast cancer patients. 
 
In Group II, 28 SLNs were identified in 27 patients.  The number of SLNs detected per patient 
ranged from 1 to 2 (the mean number of detected SLNs was 1.04). All detected SLNs were located in 
the axillary region.  
Metastases in the excised SLNs were detected in 8 patients (29.6%), who subsequently underwent 
the conventional axillary lymph node dissection. In 6 patients (22. 2%), the removed SLN and lymph 
nodes of the level II had a positive histology. In 21 patients (77.7%), the SLN was negative, with no 
clinical evidence of lymph node metastasis during the follow-up.  In this group of patients, there was 
also no phenomenon of so called “jumping” metastases.   
The percentage of phytate colloid accumulation in the SLN in 18 hours after injection was 1.5-2% 
by SPECT and 4-7% by intraoperative gamma probe detection.  
Thus, the use of phytate colloid for detecting SLNs in breast cancer patients demonstrated 90% 
sensitivity.  
Various techniques of SLN identification are widely discussed in the published literature. 
Currently, most investigators propose that the blue dye and isotope complement each other, and the 
detection of SLN is more successful using combined dye- isotope technique, with sensitivity and 
specificity approaching 100% [[10],[12]]. In our study, the use of 99mTc-Al2O3, a novel molecular 
imaging agent has shown promising results in detecting SLNs with high sensitivity and specificity. 
For histological examination of the identified sentinel lymph nodes, we used the light optical 
microscopy with hematoxylin-eosin.  A number of authors have published immunohistochemistry and 
flow cytophluorometry for the detection of micrometastases in lymph nodes, allowing a three-fold 
increase in the detection rate to be achieved [13]. The wide use of the modern methods of histological 
express analysis will significantly improve the clinical significance of detecting the sentinel lymph 
nodes in breast cancer patients.  
Thus, the use of the new radiopharmaceutical allows the precise detection of SLNs to be achieved, 
thereby personalizing the extent of surgery in patients with primary operable breast and cervical 
cancers.  
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4. Conclusion 
The novel radiopharmaceutical based on 99mTc-Al2O3has high accumulation in sentinel lymph nodes, 
with no evidence of further redistribution along the lymphatic collector, thus significantly facilitating 
scintigraphic and intraoperative SLN identification. 
The sensitivity and specificity of using 99mTc-Al2O3 were 100% for both SPECT and 
intraoperative identification of sentinel lymph nodes.   
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